Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 276

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 276
---
 of office space in Pacific Palisades, California. We exercised an
option, under our prior lease agreement, to extend the term for an additional period of three (3) years and six (6) months, until February 28, 2025, with an option to renew for an additional three (3) years in accordance with the
terms of the Pacific Palisades Lease. Included in the renewal were nine months of rent abatement and a rent escalation clause.

Rent expense is being
recorded on a straight-line basis. Rent expense related to the Pacific Palisades and Morristown leases for the nine months ended September 30, 2024 and 2023 was $0.3 million and $0.5 million and $0.4 million for the years ended
December 31, 2023 and 2022, respectively. See Note 6 to our unaudited condensed consolidated financial statements and Note 7 to the audited consolidated financial statements, each appearing elsewhere in this proxy statement for details related
to future lease payments.

- 191 -

In January 2022, we entered into a Negotiated Purchase Order Terms and Conditions for Clinical and
Commercial Product, as amended effective as of August 1, 2022, March 31, 2024, and July 31, 2024 (the “Fresenius Agreement”) with Fresenius Kabi, LLC (“Fresenius Kabi”), pursuant to which Fresenius Kabi
manufactured FYARRO for us and we purchased FYARRO as a finished drug product from Fresenius Kabi, on a purchase order basis. The Fresenius Agreement contained specific activities such as non-cancellable
commitments, minimum purchase commitments, or binding annual forecasts. Under the Fresenius Agreement, which was effective through September 30, 2024, we purchased FYARRO for either clinical or commercial purposes for use in the United States
and Canada. Although we believe we presently have sufficient supply of FYARRO for at least the next two years based on our estimated demand and are seeking to enter into a new agreement with Fresenius Kabi for the manufacture of FYARRO, if we are
unable to enter into a new agreement on favorable terms or at all, our business could be materially adversely affected.

We also have contracts with
various organizations to conduct research and development activities, including clinical trial organizations to manage clinical trial activities and manufacturing companies to manufacture the drug product